Tumor–associated antigens identified by mRNA expression profiling as tumor rejection epitopes

Thirteen H-2(b)-binding peptides derived from six potentially overexpressed proteins in p53(-/- )thymoma (SM7) cells were studied for immunogenecity and vaccine-induced prevention of tumor growth in mice inoculated with SM7 tumor cells. Six of the peptides generated specific CTL responses after immunization, but only two of these peptides (RAD(23–31 )and RAD(24–31)) were capable of generating a weak vaccination-induced protection against adoptive tumor growth. SM7 inoculated mice treated with a blocking antibody against the inhibitory T cell signal transducing molecule CTLA4 appeared to delay tumor take, suggesting that SM7 thymoma cells are recognized by the adaptive immune system of the host. However, prophylactic vaccination with RAD(23–31 )and RAD(24–31 )peptides combined with anti-CTLA4 Ab treatment and did not improve tumor resistance. Our data would indicate that vaccination with immunogenic peptides derived from potentially overexpressed tumor proteins, as identified by mRNA expression profiling of p53(-/- )thymoma cells, at best results in a weak tumor protection thus questioning this way of detection of new tumor rejection epitopes.